KB
Therapeutic Areas
Concarlo Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| p27-Targeted Therapeutic | Drug-resistant metastatic breast cancer | Preclinical |
| p27-Targeted Therapeutic Platform | Ovarian cancer, Non-small cell lung cancer (NSCLC), Melanoma | Discovery/Preclinical |
Leadership Team at Concarlo Therapeutics
DS
Dr. Stacy Blain
Founder, Chief Executive Officer
DK
Dr. Krishna Allamneni
Chief Development Officer
DG
Dr. Grace Chen
Director of Research
DC
Dr. Carolina Guido
Research Scientist
DD
Dr. Dominique Bridon
Peptide Advisor
DR
Dr. Robert DeVita
Chemistry Advisor